OBJECTIVES: To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE). METHODS: We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on second-line ART; A5288: genotype to determine the resistance profile and assign an appropriate regimen; or population-based third-line: no genotype, all patients switch to a potent third-line regimen. Model inputs are from published data in South Africa. Resistance profiles, ART regimens, and efficacy data were those used for trial planning. RESULTS: Projected life expectancy for sustained second-line, A5288, and population-based third-line are 61.1, 103.8, and 104.2 months. Compared to sustained second-line ($12 ,460), per person lifetime costs increase for the A5288 ($39, 250) and population-based ($44, 120) strategies. The incremental cost-effectiveness ratio of A5288, compared to sustained second-line, is $7500/year of life saved (YLS), and for population-based third-line, compared to A5288, is $154 ,500/YLS. In the A5288 strategy, very late presentation to care, coupled with lengthy delays to obtain the genotype, dramatically reduces 5-year survival, making the population-based third-line strategy more attractive. CONCLUSIONS: We project that, whereas the public health approach to third-line therapy is unaffordable, genotype assays and third-line ART in resource-limited settings will increase survival and be cost-effective compared to the population-based approach, supporting the value of an efficacy study.
OBJECTIVES: To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE). METHODS: We used the Cost-effectiveness of Preventing AIDS Complications (CEPAC)-International Model to compare three strategies for patients who have failed second-line ART in South Africa: sustained second-line: no genotype assay, all patients remain on second-line ART; A5288: genotype to determine the resistance profile and assign an appropriate regimen; or population-based third-line: no genotype, all patients switch to a potent third-line regimen. Model inputs are from published data in South Africa. Resistance profiles, ART regimens, and efficacy data were those used for trial planning. RESULTS: Projected life expectancy for sustained second-line, A5288, and population-based third-line are 61.1, 103.8, and 104.2 months. Compared to sustained second-line ($12 ,460), per person lifetime costs increase for the A5288 ($39, 250) and population-based ($44, 120) strategies. The incremental cost-effectiveness ratio of A5288, compared to sustained second-line, is $7500/year of life saved (YLS), and for population-based third-line, compared to A5288, is $154 ,500/YLS. In the A5288 strategy, very late presentation to care, coupled with lengthy delays to obtain the genotype, dramatically reduces 5-year survival, making the population-based third-line strategy more attractive. CONCLUSIONS: We project that, whereas the public health approach to third-line therapy is unaffordable, genotype assays and third-line ART in resource-limited settings will increase survival and be cost-effective compared to the population-based approach, supporting the value of an efficacy study.
Authors: Christine Katlama; Bonaventura Clotet; Anthony Mills; Benoit Trottier; Jean-Michel Molina; Beatriz Grinsztejn; William Towner; Richard Haubrich; Steven Nijs; Johan Vingerhoets; Brian Woodfall; James Witek Journal: Antivir Ther Date: 2010
Authors: Andrea L Ciaranello; Shahin Lockman; Kenneth A Freedberg; Michael Hughes; Jennifer Chu; Judith Currier; Robin Wood; Charles B Holmes; Sandy Pillay; Francesca Conradie; James McIntyre; Elena Losina; Rochelle P Walensky Journal: AIDS Date: 2011-02-20 Impact factor: 4.177
Authors: Steven G Deeks; Stephen J Gange; Mari M Kitahata; Michael S Saag; Amy C Justice; Robert S Hogg; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Constance A Benson; Ann C Collier; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; Margot B Kushel; James J Goedert; Rosemary G McKaig; Richard D Moore Journal: Clin Infect Dis Date: 2009-11-15 Impact factor: 9.079
Authors: Suely H Tuboi; Martin W G Brinkhof; Matthias Egger; Roslyn A Stone; Paula Braitstein; Denis Nash; Eduardo Sprinz; François Dabis; Lee H Harrison; Mauro Schechter Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes Journal: Clin Infect Dis Date: 2008-05-15 Impact factor: 9.079
Authors: Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Sonia Napravnik; Jessica R Keys; E Byrd Quinlivan; David A Wohl; Oksana V Mikeal; Joseph J Eron Journal: AIDS Date: 2007-04-23 Impact factor: 4.177
Authors: Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Beatriz Grinsztejn; Michael D Hughes; Justin Ritz; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Robert Gross; Catherine Godfrey; Sandra W Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Faesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Anchalee Avihingsanon; Breno R Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T Schooley; John W Mellors; Carole L Wallis; Ann C Collier Journal: Lancet HIV Date: 2019-07-29 Impact factor: 12.767
Authors: Paula M Luz; Beatriz Grinsztejn; Valdilea G Veloso; A David Paltiel Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731
Authors: Pamela P Pei; Milton C Weinstein; X Cynthia Li; Michael D Hughes; A David Paltiel; Taige Hou; Robert A Parker; Melanie R Gaynes; Paul E Sax; Kenneth A Freedberg; Bruce R Schackman; Rochelle P Walensky Journal: HIV Clin Trials Date: 2015-12-11
Authors: Eric N Ouattara; Eric L Ross; Yazdan Yazdanpanah; Angela Y Wong; Marion Robine; Elena Losina; Raoul Moh; Rochelle P Walensky; Christine Danel; A David Paltiel; Serge P Eholié; Kenneth A Freedberg; Xavier Anglaret Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731
Authors: T Heller; P Ganesh; J Gumulira; L Nkhoma; C Chipingu; C Kanyama; T Kalua; R Nyrienda; S Phiri; A Schooley Journal: Public Health Action Date: 2019-12-21